Medicilon(SH:688202) Sou Hu Wang·2026-01-19 01:05Core Insights - The ACCESS ASIA BD Forum @JPM2026 highlighted the strategic role of Asia, particularly China, in global biopharmaceutical innovation and transactions, showcasing the capabilities of companies like Mediso in drug development partnerships [1][2]. Group 1: Company Contributions - Mediso demonstrated its integrated capabilities as a drug development partner, emphasizing its transition from a "service provider" to an "innovation ecosystem builder" within the Chinese CRO industry [1]. - The company’s comprehensive R&D service platform covers drug discovery, pharmaceutical research, and preclinical studies, significantly shortening development cycles and providing essential technical support for global licensing [1]. - Mediso's President, Dr. Duan Maosheng, presented case studies illustrating the CRO's increasing importance in complex target validation and differentiated molecular design [1]. Group 2: Industry Trends - Experts at the forum agreed that Chinese innovative drug assets are rapidly integrating into the global R&D system, with Mediso facilitating clients in asset valuation and international collaboration [2]. - The discussions highlighted new cooperation models and growth points arising from the globalization of markets, capital, and technology, with Asia, especially China, becoming an indispensable part of the global biopharmaceutical value chain [2]. - The forum served as a valuable platform for global biopharmaceutical ecosystems, emphasizing the critical role of Chinese R&D service companies in promoting international collaboration [3]. Group 3: Event Highlights - Mediso showcased its client posters and casebook, "The Blueprint: A Portfolio of Executed Programs," which attracted significant attention and illustrated the company's interdisciplinary and cross-regional R&D service capabilities [3]. - The event featured various presentations and discussions that underscored Mediso's strength as an integrated partner in drug development and its commitment to driving innovation [3].